Ftse Mib
33.556,81
1,01%
DAX
18.165,23
0,54%
S&P 500
5.487,03
0,25%
NASDAQ
0,00
0,00%
Bitcoin
66.175,77
1,86%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Finch Therapeutics Group Inc (FNCH) Finch Therapeutics Group Inc (FNCH) Notizie

FNCH

Finch Therapeutics (FNCH)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FNCH
DataOraFonteTitoloSimboloCompagnia
24/05/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FNCHFinch Therapeutics Group Inc
10/05/202422:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FNCHFinch Therapeutics Group Inc
13/12/202323:20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FNCHFinch Therapeutics Group Inc
11/08/202312:31Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:FNCHFinch Therapeutics Group Inc
28/06/202322:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FNCHFinch Therapeutics Group Inc
23/06/202322:31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:FNCHFinch Therapeutics Group Inc
09/06/202322:53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FNCHFinch Therapeutics Group Inc
09/06/202313:00GlobeNewswire Inc.Finch Announces Reverse Stock Split of Common StockNASDAQ:FNCHFinch Therapeutics Group Inc
16/05/202322:17Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FNCHFinch Therapeutics Group Inc
11/05/202322:13Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:FNCHFinch Therapeutics Group Inc
10/05/202313:15Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:FNCHFinch Therapeutics Group Inc
10/05/202313:00GlobeNewswire Inc.Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:FNCHFinch Therapeutics Group Inc
26/04/202322:05Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:FNCHFinch Therapeutics Group Inc
26/04/202322:02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:FNCHFinch Therapeutics Group Inc
25/04/202322:05GlobeNewswire Inc.Finch Therapeutics Announces Executive Leadership TransitionsNASDAQ:FNCHFinch Therapeutics Group Inc
18/04/202322:01GlobeNewswire Inc.Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License AgreementNASDAQ:FNCHFinch Therapeutics Group Inc
14/04/202322:08Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:FNCHFinch Therapeutics Group Inc
23/03/202321:25Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:FNCHFinch Therapeutics Group Inc
23/03/202321:05GlobeNewswire Inc.Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesNASDAQ:FNCHFinch Therapeutics Group Inc
24/01/202314:00GlobeNewswire Inc.Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other AssetsNASDAQ:FNCHFinch Therapeutics Group Inc
10/11/202213:00GlobeNewswire Inc.Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial ResultsNASDAQ:FNCHFinch Therapeutics Group Inc
09/11/202214:00GlobeNewswire Inc.Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx ConferenceNASDAQ:FNCHFinch Therapeutics Group Inc
24/10/202214:00GlobeNewswire Inc.Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile InfectionNASDAQ:FNCHFinch Therapeutics Group Inc
01/09/202214:00GlobeNewswire Inc.Finch Therapeutics Provides Business UpdateNASDAQ:FNCHFinch Therapeutics Group Inc
25/08/202222:30GlobeNewswire Inc.Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBDNASDAQ:FNCHFinch Therapeutics Group Inc
11/08/202213:00GlobeNewswire Inc.Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial ResultsNASDAQ:FNCHFinch Therapeutics Group Inc
03/06/202212:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:FNCHFinch Therapeutics Group Inc
02/06/202213:00GlobeNewswire Inc.Finch Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:FNCHFinch Therapeutics Group Inc
17/05/202214:00GlobeNewswire Inc.Finch Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:FNCHFinch Therapeutics Group Inc
16/05/202213:00GlobeNewswire Inc.Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ResultsNASDAQ:FNCHFinch Therapeutics Group Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FNCH

La tua Cronologia

BIT
P1ZV06
NLBNPIT1ZV06 20991231 20...
NASDAQI
HX451010GI
OMX Helsinki Beverages GI
NYSE
TRP
TC Energy
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network